# Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Source: https://onco.cc/trials/nct07576725/  
OnCo record `nct07576725` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of nivolumab in colorectal cancer, run by Fred Hutchinson Cancer Center, not yet recruiting.

## Summary

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial is a phase 2, interventional study registered as NCT07576725 by Fred Hutchinson Cancer Center, with a registry enrolment figure of 50 participants, started 2026-12-01 and due to reach its primary completion in 2029-08-31. Interventions recorded: Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Nivolumab. Conditions listed: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Hodgkin Lymphoma; Kaposi Sarcoma; Metastatic Acral Lentiginous Melanoma; Metastatic Basal Cell Carcinoma; Metastatic Cervical Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Metastatic Colorectal Carcinoma; Metastatic Cutaneous Melanoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Kaposi Sarcoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Merkel Cell Carcinoma; Metastatic Mucosal Melanoma; Metastatic Skin Squamous Cell Carcinoma; Metastatic Urothelial Carcinoma; Stage III Cervical Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Acral Lentiginous Melanoma; Unresectable Basal Cell Carcinoma; Unresectable Cervical Carcinoma; Unresectable Clear Cell Renal Cell Carcinoma; Unresectable Colorectal Carcinoma; Unresectable Cutaneous Melanoma; Unresectable Head and Neck Squamous Cell Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Malignant Solid Neoplasm; Unresectable Merkel Cell Carcinoma; Unresectable Mucosal Melanoma; Unresectable Skin Squamous Cell Carcinoma; Unresectable Urothelial Carcinoma. Primary outcome: Objective response. Colorectal eligibility wording from the registry: "* Colorectal cancer with high microsatellite instability (MSI) or mismatch repair deficiency". Sites: Uganda. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07576725
- Phase: 2
- Setting: AFFORD IO: A Phase 2 Trial of Low Dose, Reduced Frequency Nivolumab (Anti-PD-1 Antibody) in Patients With Unresectable or Metastatic Cancer
- Sponsor: Fred Hutchinson Cancer Center
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07576725: https://clinicaltrials.gov/study/NCT07576725

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07576725.json